Otsuka (OTCMKTS:OTSKY) Issues FY 2026 Earnings Guidance

Otsuka (OTCMKTS:OTSKY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.639-1.639 for the period, compared to the consensus estimate of 0.000. The company issued revenue guidance of $16.4 billion-$16.4 billion, compared to the consensus revenue estimate of $16.4 billion.

Analyst Ratings Changes

OTSKY has been the topic of several research analyst reports. UBS Group raised Otsuka to a “hold” rating in a research note on Tuesday, January 27th. Morgan Stanley raised Otsuka to an “overweight” rating in a research report on Friday, January 23rd. Finally, Zacks Research lowered Otsuka from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Otsuka Stock Down 2.8%

Otsuka stock traded down $0.96 during mid-day trading on Tuesday, reaching $33.70. The company’s stock had a trading volume of 21,023 shares, compared to its average volume of 34,923. Otsuka has a 12 month low of $21.64 and a 12 month high of $34.93. The business’s 50 day simple moving average is $29.68 and its 200 day simple moving average is $28.14.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.